Acutaas Chemicals Reports Record FY26 Profit on CDMO Strength, Diversification

Acutaas Chemicals Limited announced a record Profit After Tax (PAT) of ₹356.4 crores for the fiscal year 2026, driven significantly by its Contract Development and Manufacturing Organisation (CDMO) business. The company's Advanced Pharmaceutical Intermediates segment, a key part of its CDMO operations, achieved robust year-on-year revenue growth of 43.9% in the fourth quarter of FY26.

The company is actively expanding into new sectors, including battery chemicals and semiconductor materials. Acutaas has commercialized two battery chemical products and plans to launch two more in FY27. Shipments for semiconductor materials have already begun to customers in Japan and South Korea. Acutaas also invested ₹190 crores in its South Korea joint venture, Indichem Inc., which now has an operational R&D center.

Management has guided for 25% revenue growth in FY27 and expects to maintain consolidated EBITDA margins at FY26 levels, which ranged between 34.5% and 35%.

However, Acutaas faces several challenges. Geopolitical conflicts in the Gulf region are disrupting feedstock supply chains and driving up raw material prices. Global shipping disruptions and an increase in working capital days to 120 from 114 also present operational hurdles.

Acutaas Chemicals, formerly Ami Organics, officially changed its name in July 2023. This rebranding signals a strategic shift toward becoming a multi-vertical chemical solutions provider, supported by plans for a tenfold expansion of its R&D capabilities.

In the pharmaceutical CDMO market, Acutaas competes with companies like Divi's Laboratories and Laurus Labs. Acutaas differentiates itself by actively diversifying into high-potential areas such as battery chemicals and semiconductor materials, a strategy less common among its direct CDMO-focused peers.

Investors will be focused on the company's execution of its guided 25% revenue growth for FY27, the performance and ramp-up of its new battery chemical and semiconductor products, and progress on R&D expansion. Key areas to monitor also include management's strategies for navigating supply chain and shipping risks, the revenue generation from the Indichem JV, and the working capital cycle.